1. The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression.
- Author
-
Wei, Jin, Alfajaro, Mia, Cai, Wesley, Graziano, Vincent, Strine, Madison, Filler, Renata, Biering, Scott, Sarnik, Sylvia, Patel, Sonam, Menasche, Bridget, Compton, Susan, Konermann, Silvana, Hsu, Patrick, Orchard, Robert, Yan, Qin, and Wilen, Craig
- Subjects
Animals ,Humans ,Mice ,Angiotensin-Converting Enzyme 2 ,COVID-19 ,Dipeptidyl Peptidase 4 ,Histone Demethylases ,Middle East Respiratory Syndrome Coronavirus ,Receptors ,Virus ,SARS-CoV-2 - Abstract
Identification of host determinants of coronavirus infection informs mechanisms of pathogenesis and may provide novel therapeutic targets. Here, we demonstrate that the histone demethylase KDM6A promotes infection of diverse coronaviruses, including SARS-CoV, SARS-CoV-2, MERS-CoV and mouse hepatitis virus (MHV) in a demethylase activity-independent manner. Mechanistic studies reveal that KDM6A promotes viral entry by regulating expression of multiple coronavirus receptors, including ACE2, DPP4 and Ceacam1. Importantly, the TPR domain of KDM6A is required for recruitment of the histone methyltransferase KMT2D and histone deacetylase p300. Together this KDM6A-KMT2D-p300 complex localizes to the proximal and distal enhancers of ACE2 and regulates receptor expression. Notably, small molecule inhibition of p300 catalytic activity abrogates ACE2 and DPP4 expression and confers resistance to all major SARS-CoV-2 variants and MERS-CoV in primary human airway and intestinal epithelial cells. These data highlight the role for KDM6A-KMT2D-p300 complex activities in conferring diverse coronaviruses susceptibility and reveal a potential pan-coronavirus therapeutic target to combat current and emerging coronaviruses. One Sentence Summary: The KDM6A/KMT2D/EP300 axis promotes expression of multiple viral receptors and represents a potential drug target for diverse coronaviruses.
- Published
- 2023